Physician profile
Fatima Ali Eidy
NPI 1780193748
$7,123.14
in general payments reported to CMS, 2019-2025
39 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,400 · 2022: $1,716 · 2023: $1,601 · 2024: $984 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,007.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $663.43 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $646.29 | 2021-2025 | Jardiance, Emgality, Mounjaro |
| Ironwood Pharmaceuticals, INC | $579.66 | 2021-2025 | Linzess |
| Amgen INC. | $450.05 | 2021-2025 | Repatha, Repatha, Otezla |
| Corcept Therapeutics | $433.36 | 2022-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $421.67 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Abbvie INC. | $397.03 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $381.15 | 2021-2024 | Xarelto |
| Pfizer INC. | $371.89 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $371.61 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $302.55 | 2021-2025 | |
| Glaxosmithkline, LLC. | $298.48 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Cequr Corporation | $192.61 | 2023-2025 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.47 | 2021-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $166.21 | 2023-2025 | Auvelity, Symbravo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $162.88 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.98 | 2021-2024 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Ardelyx, INC. | $121.23 | 2023-2025 | Ibsrela |
| Exact Sciences Corporation | $113.06 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $91.86 | 2024-2025 | Gemtesa |
| Dexcom, INC. | $91.13 | 2022-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $77.85 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.16 | 2023-2024 | Trintellix |
| Abbott Laboratories | $61.92 | 2021-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $58.04 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $38.06 | 2021 | |
| Vanda Pharmaceuticals INC. | $31.94 | 2021 | |
| Redhill Biopharma INC. | $28.30 | 2021 | |
| Verona Pharma, INC. | $20.52 | 2025 | Ohtuvayre |
| Otsuka America Pharmaceutical, INC. | $20.00 | 2021 | |
| Azurity Pharmaceuticals, INC. | $19.88 | 2025 | Edarbi |
| Xeris Pharmaceuticals, INC. | $18.49 | 2024 | Recorlev |
| Biohaven Pharmaceutical Holding Company LTD. | $17.50 | 2022 | |
| Esperion Therapeutics, INC. | $17.08 | 2025 | Nexletol |
| Aimmune Therapeutics, INC. | $16.84 | 2024 | |
| Nestle Healthcare Nutrition INC. | $15.76 | 2023 | |
| Eisai INC. | $13.32 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.23 | 2021 | |
| Allergan, INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fatima Eidy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.